The bill amends section 1192(e) of the Social Security Act to change how the Drug Price Negotiation Program calculates elapsed time since a drug’s approval or a biologic’s licensure. It directs the Secretary of HHS not to count any period during which the product held orphan status when computing the elapsed time used to determine negotiation eligibility.
The change applies to both drugs and biologics and is framed as an exclusion for "former orphan drugs."
The bill also revises the orphan definition language in the statute from “only one rare disease or condition” to “one or more rare diseases or conditions,” and ties that phrasing to the definition in FDCA section 526(a)(2). Practically, the bill pauses the DP Program’s eligibility clock for the duration a product is designated as an orphan and potentially expands which products qualify for that pause — a change that can extend the period before a product becomes eligible for government negotiation and thereby affect Medicare spending, payer negotiating leverage, and industry incentives for rare-disease development.
At a Glance
What It Does
The bill instructs the HHS Secretary to exclude from the elapsed-time calculation any period during which a drug or biologic was designated an orphan product when determining timing triggers in the Drug Price Negotiation Program. It also changes statutory language to cover products designated for “one or more rare diseases or conditions,” referencing the FDCA definition.
Who It Affects
Manufacturers of orphan-designated drugs and biologics — including products that gain additional rare-disease approvals later — HHS/CMS administrators who run the negotiation program, and payers (Medicare, Medicaid, private insurers) whose leverage and timing for negotiated prices could be delayed.
Why It Matters
By pausing the negotiation clock for orphan periods, the bill preserves more time before products face government price negotiation, reinforcing incentives tied to orphan designation. That timing shift can materially affect when expensive specialty drugs enter negotiated pricing and thus alter federal and commercial drug spending trajectories.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The ORPHAN Cures Act makes two narrow but consequential edits to the Drug Price Negotiation Program language in title XI of the Social Security Act. First, it adds a rule that when the statute instructs the Secretary to calculate how long it has been since a drug’s approval or a biologic’s licensure (the elapsed-time tests that feed into negotiation eligibility), the Secretary must ignore any span of time during which the product was an orphan-designated drug.
In practice, this means the statutory “clock” that moves a product toward negotiation eligibility is paused for all periods the product held orphan status.
Second, the bill alters the descriptive language used to identify orphan drugs in that section. It replaces the narrower phrasing that referenced “only one rare disease or condition” with “one or more rare diseases or conditions” and explicitly points to the FDCA definition (section 526(a)(2)).
That change aligns the Drug Price Negotiation text with the FDA statutory definition and broadens the statute to cover products designated for multiple rare indications.Together, these changes create a procedural rule and a definitional tweak. The procedural rule forces the negotiation administrator to consult orphan designation history when computing timing triggers; the definitional tweak increases the set of products that can qualify as orphan products for the purpose of that exclusion.
The bill does not alter substantive orphan exclusivity under the FDCA, nor does it change other price or reimbursement rules — it narrowly targets how time-to-eligibility is measured for the negotiation program.
The Five Things You Need to Know
The bill adds a new subparagraph directing the HHS Secretary not to count any period during which a drug or biologic was an orphan-designated product when calculating elapsed time tied to negotiation eligibility.
The amendment explicitly applies to both drugs (approval) and biological products (licensure) by referencing the statute’s approval and licensure subparagraphs.
It changes statutory language to cover products for “one or more rare diseases or conditions” and cross-references the FDCA definition in section 526(a)(2).
By excluding orphan-designated periods from the elapsed-time calculation, the bill effectively pauses the ‘clock’ that determines when a product becomes eligible for Drug Price Negotiation.
Implementation will require HHS to rely on FDA orphan-designation records and creates an opportunity for manufacturers to use orphan status strategically to delay negotiation eligibility.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: ORPHAN Cures Act
Provides the Act’s short title. This is a standard drafting clause that identifies the bill as the "Optimizing Research Progress Hope And New Cures Act" or "ORPHAN Cures Act." It has no programmatic effect but frames the statutory change under that banner.
Exclude orphan-designation periods from elapsed-time calculations
Adds a new subparagraph (C) to paragraph (1) instructing the Secretary not to count any period during which the drug or biologic was an orphan product when calculating the elapsed time referenced elsewhere in the statute. Mechanically, this requires CMS (or the HHS official responsible) to identify the start and end dates of orphan designation periods and subtract those intervals from the elapsed-time metric that triggers negotiation eligibility. Practically, that subtraction delays the moment a product meets the time-based thresholds in subparagraphs A(ii) and B(ii).
Broaden orphan-description language and reference FDA definition
Revises paragraph (3)(A) by replacing text that limited orphan status references to “only one rare disease or condition” with “one or more rare diseases or conditions,” and links the phrase to the FDCA definition in 526(a)(2). This clarifies that products designated for multiple rare indications fall within the statute’s orphan-drug description for the purposes of the exclusion, and it aligns statutory language with FDA’s definitional framework — making FDA records the natural evidence source for implementation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Pharmaceutical and biotech sponsors of orphan-designated products — they gain more time before entering government price negotiations because the bill pauses the elapsed-time clock during orphan designation periods.
- Smaller rare-disease developers and investors — the change strengthens the value of obtaining orphan designation (including for multiple indications), protecting revenue windows investors rely on and potentially improving financing prospects.
- Manufacturers that obtain temporary or sequential orphan designations — the bill allows any period with orphan status to be excluded, so companies that sequence or expand orphan approvals can preserve additional time before negotiation.
Who Bears the Cost
- HHS/CMS — the agency must add processes to identify, verify, and subtract orphan-designation periods from elapsed-time calculations, increasing administrative work and potential for disputes with sponsors.
- Medicare, Medicaid, and commercial payers — delaying negotiation eligibility keeps certain high-cost drugs off negotiated-pricing schedules for longer, likely sustaining higher prices for payers and beneficiaries.
- Taxpayers and federal budget — postponed negotiation could mean higher federal prescription drug spending over the periods that remain excluded from timing calculations.
Key Issues
The Core Tension
The central dilemma is between preserving incentives that encourage development of treatments for rare diseases — by allowing orphan-designated periods to pause negotiation eligibility — and Congress’s goal to lower drug prices through timely government negotiation. Pausing the negotiation clock protects manufacturer revenue windows and R&D incentives but does so at the cost of delaying price negotiation and maintaining higher payer spending; the statute provides a blunt tool without prescribing how to prevent gaming or manage operational complexities.
The bill solves a narrow timing problem but raises several operational and policy questions. Operationally, HHS must decide how to define the exact start and end of an orphan-designation period for calculation purposes: whether to rely on FDA’s orphan designation date, the sponsor’s request, or another administrative milestone.
The statute’s instruction to "not take into account any period during which such drug or product was a drug described in paragraph (3)(A)" is concise but silent on retroactivity and on how to handle overlapping or intermittent orphan designations, amendments to orphan status, or designations that post-date approval. Those gaps will require implementing guidance or regulation.
On policy, the change creates an attractive pathway for manufacturers to influence negotiation timing through orphan-designation strategy. Because the bill counts any orphan period toward an exclusion, sponsors may seek orphan designations for narrow subpopulations or pursue sequential orphan approvals to preserve market advantages even after broader approvals.
That dynamic intensifies the classic trade-off between encouraging rare-disease R&D and achieving timely price reductions for expensive therapies. The bill does not alter orphan exclusivity or the substantive criteria the FDA uses — but it does change economic incentives by linking designation status to negotiation timing, and it leaves enforcement and dispute resolution details to future administrative action.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.